If you can carry out research that supports program objectives of NIAID’s Division of Microbiology and Infectious Diseases (DMID), consider submitting a proposal through the 2022 NIAID Omnibus Broad Agency Announcement (BAA) contract solicitation.
DMID will use this BAA to help address the goals of strategic plans and new pandemic preparedness programs. Contract funds will support vaccine and therapeutic development through candidate testing; product manufacture; preclinical or nonclinical toxicology testing; and early clinical studies.
As we summarize below, the 2022 BAA covers four distinct research areas. You may respond to one, any combination of, or all the research areas. For each research area, be sure to present separate, detailed technical and business proposals designed to meet the technical objectives described.
For all four research areas:
- Contact: Direct your inquiries to Julie Rodriguez, the contracting officer, at 301-761-7735 or julie.rodriguez@nih.gov.
- Performance Period: Not to exceed five years (base plus options).
- Proposal Submission: Online through the electronic Contract Proposal Submission (eCPS) website.
Research Area 001: Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases
- Description: Supports advancing vaccine candidates, technologies, and platforms that could be deployed against agents that include category A, B, and C NIAID Emerging Infectious Diseases and Pathogens and AMR organisms.
- Number of Awards, Total Costs: For fiscal year (FY) 2023, NIAID estimates it will award up to $12.8 million total for the non-severable base period of five or six cost-reimbursement type contracts across research areas 001, 002, and 004.
- Due Date: April 18, 2022, by 3 p.m. Eastern Time.
Research Area 002: Development of Therapeutic Candidates for Biodefense, AMR Infections, and Emerging Infectious Diseases
- Description: Supports the development of promising new therapeutics to address infections and diseases caused by NIAID Emerging Infectious Diseases and Pathogens (including category A, B, and C priority pathogens) and selected bacterial and fungal pathogens identified in the CDC 2019 Antibiotic Resistance Threats in the United States report.
- Number of Awards, Total Costs: For FY 2023, NIAID estimates it will award up to $12.8 million total for the non-severable base period of five or six cost-reimbursement type contracts across research areas 001, 002, and 004.
- Due Date: April 18, 2022, by 3 p.m. Eastern Time.
Research Area 003: The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential
- Description: Supports the development of antivirals as described in the Antiviral Program for Pandemics. NIAID encourages proposals to develop broad-spectrum therapeutics with extended therapeutic activity over more than one pathogen. Therapeutic candidates with a narrower spectrum of activity against priority viruses are also eligible.
- Number of Awards, Total Costs: For FY 2023, NIAID estimates it will award up to $34 million total for the non-severable base period of two or more cost-reimbursement type contracts.
- Due Date: March 18, 2022, by 3 p.m. Eastern Time.
Research Area 004: Development of In Vitro Diagnostics for Biodefense, AMR Infections, and Emerging Infectious Diseases
- Description: Supports the development of promising diagnostics technologies for detection of signatures from biothreat pathogens and pathogens causing emerging, reemerging, and AMR infectious diseases, and for pandemic preparedness.
- Number of Awards, Total Costs: For FY 2023, NIAID estimates it will award up to $12.8 million total for the non-severable base period of five or six cost-reimbursement type contracts across research areas 001, 002, and 004.
- Due Date: April 18, 2022, by 3 p.m. Eastern Time.
Find complete details in the solicitation as well as any amendments issued since we went to press.